Profile data is unavailable for this security.
About the company
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. The Company also has two cardiac pipeline gene transfer programs, SGT-601 for TNNT2 DCM and SGT-701 for RBM20 DCM, that are both in early preclinical development. It also has a neuromuscular gene transfer program for the treatment of Friedreich's ataxia. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including novel capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
- Revenue in USD (TTM)0.00
- Net income in USD-90.69m
- Incorporated2013
- Employees88.00
- LocationSolid Biosciences Inc500 RUTHERFORD AVENUE, 3RD FLOORCHARLESTOWN 02129United StatesUSA
- Phone+1 (617) 337-4680
- Fax+1 (302) 655-5049
- Websitehttps://www.solidbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ESSA Pharma Inc | 0.00 | -27.67m | 286.62m | 50.00 | -- | 2.22 | -- | -- | -0.6257 | -0.6257 | 0.00 | 2.90 | 0.00 | -- | -- | 0.00 | -19.33 | -23.01 | -19.81 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
| Akebia Therapeutics Inc | 174.50m | -40.44m | 288.09m | 167.00 | -- | -- | -- | 1.65 | -0.2024 | -0.2024 | 0.8803 | -0.1608 | 0.7364 | 1.36 | 7.07 | 1,044,892.00 | -17.07 | -37.42 | -29.47 | -56.00 | 82.59 | 69.13 | -23.18 | -82.25 | 0.8222 | -4.41 | 8.89 | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
| Tscan Therapeutics Inc | 12.20m | -104.41m | 292.42m | 175.00 | -- | 1.14 | -- | 23.97 | -1.05 | -1.05 | 0.1225 | 4.82 | 0.0353 | -- | -- | 79,220.78 | -30.19 | -- | -33.78 | -- | -- | -- | -855.84 | -- | -- | -- | 0.1066 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
| Tectonic Therapeutic Inc | 0.00 | -58.25m | 295.87m | 13.00 | -- | 1.78 | -- | -- | -18.52 | -18.52 | 0.00 | 11.29 | 0.00 | -- | -- | 0.00 | -35.55 | -45.22 | -40.16 | -49.14 | -- | -- | -- | -- | -- | -128.75 | 0.0066 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
| PepGen Inc | 0.00 | -89.14m | 299.83m | 64.00 | -- | 1.92 | -- | -- | -3.30 | -3.30 | 0.00 | 4.78 | 0.00 | -- | -- | 0.00 | -47.47 | -- | -52.97 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
| Zentalis Pharmaceuticals Inc | 40.56m | -194.65m | 300.08m | 168.00 | -- | 0.7843 | -- | 7.40 | -2.75 | -2.75 | 0.5719 | 5.38 | 0.0729 | -- | 15.94 | 241,428.60 | -34.99 | -47.40 | -39.16 | -54.18 | -- | -- | -480.07 | -- | -- | -- | 0.00 | -- | -- | -- | -23.39 | -- | 20.76 | -- |
| Artiva Biotherapeutics Inc | -100.00bn | -100.00bn | 302.62m | 82.00 | -- | -- | -- | -- | -- | -- | -- | 1.09 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0087 | -- | 579.21 | -- | 51.15 | -- | -- | -- |
| Solid Biosciences Inc | 0.00 | -90.69m | 303.36m | 88.00 | -- | 1.57 | -- | -- | -3.30 | -3.30 | 0.00 | 5.01 | 0.00 | -- | -- | 0.00 | -41.63 | -49.99 | -44.77 | -56.25 | -- | -- | -- | -2,117.05 | -- | -- | 0.0076 | -- | -100.00 | -- | -11.67 | -- | -27.90 | -- |
| Sutro Biopharma Inc | 169.36m | -124.45m | 309.00m | 304.00 | -- | 2.03 | -- | 1.82 | -1.84 | -1.84 | 2.56 | 1.86 | 0.3551 | -- | 19.98 | 560,791.40 | -26.09 | -25.48 | -32.89 | -29.75 | -- | -- | -73.48 | -113.71 | -- | -- | 0.00 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
| Atea Pharmaceuticals Inc | 0.00 | -176.00m | 309.83m | 75.00 | -- | 0.6503 | -- | -- | -2.10 | -2.10 | 0.00 | 5.64 | 0.00 | -- | -- | 0.00 | -30.97 | -5.90 | -32.19 | -6.98 | -- | -- | -- | -38.91 | -- | -- | 0.00 | -- | -- | -- | -17.30 | -- | -- | -- |
| Editas Medicine Inc | 67.03m | -193.45m | 310.94m | 265.00 | -- | 1.34 | -- | 4.64 | -2.36 | -2.36 | 0.8183 | 2.81 | 0.1447 | -- | 52.99 | 252,954.70 | -41.75 | -29.85 | -48.49 | -33.19 | -- | -- | -288.59 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
| Heron Therapeutics Inc | 136.36m | -48.13m | 312.44m | 126.00 | -- | -- | -- | 2.29 | -0.3249 | -0.3249 | 0.9094 | -0.2503 | 0.6503 | 1.08 | 1.81 | 1,082,230.00 | -22.95 | -53.55 | -38.15 | -71.24 | 65.49 | 52.52 | -35.29 | -170.12 | 1.85 | -- | 1.34 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
| Biomea Fusion Inc | 0.00 | -139.65m | 312.86m | 112.00 | -- | 3.01 | -- | -- | -3.90 | -3.90 | 0.00 | 2.87 | 0.00 | -- | -- | 0.00 | -72.58 | -- | -80.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
| enGene Holdings Inc | 0.00 | -123.44m | 318.79m | 33.00 | -- | 1.38 | -- | -- | -4.77 | -4.77 | 0.00 | 5.21 | 0.00 | -- | -- | 0.00 | -78.13 | -- | -84.20 | -- | -- | -- | -- | -- | -- | -3.14 | 0.0906 | -- | -- | -- | -260.87 | -- | -- | -- |
| Ocugen Inc | 8.19m | -45.87m | 319.52m | 65.00 | -- | 16.88 | -- | 39.01 | -0.1785 | -0.1785 | 0.0319 | 0.0658 | 0.1265 | -- | -- | 126,015.40 | -78.54 | -83.56 | -103.70 | -97.79 | -- | -- | -620.91 | -2,921.94 | -- | -- | 0.1445 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
| ADC Therapeutics SA | 66.75m | -214.86m | 321.84m | 273.00 | -- | -- | -- | 4.82 | -2.55 | -2.55 | 0.7802 | -1.36 | 0.1519 | 0.2704 | 2.86 | 244,490.80 | -47.51 | -48.41 | -56.37 | -55.63 | 92.99 | -- | -312.84 | -308.62 | 5.90 | -4.63 | 1.44 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
Data as of Sep 20 2024. Currency figures normalised to Solid Biosciences Inc's reporting currency: US Dollar USD
64.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 31 Mar 2024 | 6.91m | 18.00% |
| RA Capital Management LPas of 11 Jun 2024 | 4.33m | 11.28% |
| Adage Capital Management LPas of 31 Mar 2024 | 2.54m | 6.62% |
| Invus Public Equities Advisors LLCas of 25 Jul 2024 | 2.51m | 6.54% |
| Millennium Management LLCas of 30 May 2024 | 2.01m | 5.25% |
| Janus Henderson Investors US LLCas of 31 Mar 2024 | 1.81m | 4.71% |
| SilverArc Capital Management LLCas of 31 Mar 2024 | 1.33m | 3.45% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.24m | 3.22% |
| Vestal Point Capital LPas of 31 Mar 2024 | 1.04m | 2.70% |
| Finepoint Capital LPas of 31 Mar 2024 | 961.25k | 2.51% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
